In this report, we describe a case of metastatic non‐myofibroblastic sarcoma of soft tissue harbouring an EML4‐ALK fusion with dramatic clinical and radiologic response to alectinib then lorlatinib and a maintained normal quality of life of 10 months as a result of targeted therapy. Here, ALK is linked to sarcoma.